TokenPost·

Autolus Raises 2026 AUCATZYL Revenue Outlook to at Least $150 Million

Your call?

Third-quarter net product revenue increased 95% year over year to $41.2 million. Initial BOBCAT data in progressive multiple sclerosis is planned for October 2027.

Share

More news